Novus Acquisition and Development, Corp.
19.7.2021 14:32:37 CEST | ACCESS Newswire | Press release
Proud to be Aligned with a Proprietary Prescription Drug Benefits Powerhouse As We Begin Our Roll Out To Their Distribution Base
MIAMI, FL / ACCESSWIRE / July 19, 2021 / Novus Acquisition and Development, Corp. (OTC PINK:NDEV), through its wholly-owned subsidiary WCIG Insurance Services, LLC., is a hybrid health insurance entity and, the nation's first carrier offering cannabis health plans to recreational and medicinal users, is pleased to announce that it has finalized its partnership deal with PRAM to distribute, facilitate, and market the cannabis benefits package across the country.
PRAM, based in Brea, CA, is a leading pharmacy consulting and underwriting firm. The two companies working together will play a key role in the future of applying cannabis to American health plans as the United States approaches full federal legalization.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Novus is proud to have come to terms with PRAM and its 32+ years of experience as a proprietary prescription Drug Benefits Consulting and Managing General Underwriter company that provides pharmacy cost containment in the marketplace. Their primary focus is:
- Employer Groups: PRAM's client base of organizations that focus on pairing PRAM's pharmacy benefit programs alongside medical and ancillary products include distribution partners, consultants, brokers, agents, and insurance carriers across the country.
- Insurance Carriers + Pharmacy Benefit Managers (PBMs): PRAM designs cost savings pharmacy programs by coordinating insurance carriers and PBMs in an effort to help clients manage pharmacy risk. As a fundamental process, PRAM's focus is to create, underwrite, manage, and market prescription drug insurance programs. These plans are advantageously paired with limited medical, short-term medical, and GAP plans. The most beneficial element to these plans is that they are guaranteed issue and ready to take to market. PRAM has many other custom product offerings in the pharmacy space aimed at saving money and creating healthier populations.
- Plan Design Choices: PRAM intends to customize the Novus cannabis offering by tailoring formularies, copays, deductibles, specialty drug coverage, and specific drug inclusions or exclusions to best benefit the member experience.
Lisa Collier, CEO of PRAM, states: "Such innovation is at the core of PRAM's growth strategies and benefit design goals, so we are thrilled to be a part of a program that screams forward-thinking. National legalization is coming, and we'd rather be leading the dispensary network discount initiative than lagging behind it."
Frank Labrozzi, CEO of Novus, states: "It is of critical importance in business to foresee coming events. Our mission is to have the right alliance in preparation for that change. PRAM will provide that company partnership necessary for opening doors that once were challenges."
Alignment Competitive Advantages:
With the PRAM alliance, Novus is positioned to play a greater role in the future in the following areas:
- More doctors will recommend medical cannabis as participation in reducing opiate prescriptions.
- Take the stigma out of cannabis in the workplace with precedence set in the New Jersey Supreme Court, that ruled, under the New Jersey Law Against Discrimination ("LAD"), employees who legally use cannabis as permitted by the state's Compassionate Use of Cannabis of Medical Marijuana Act[i] may not be fired.
- Ending prohibitions we could see a dramatic increase in our Provider Network where the big box and boutique retailers will likely sell pre-packaged cannabis in smokable and edible forms.
As Washington has to make up for a $6 Trillion dispersal of money in the past 18 months, there has never been a more critical time to legalize cannabis. More importantly, by ending prohibition of cannabis we will see med and rec users encouragingly help support our economy as they choose to have cannabis as a part of health insurance benefits.
Research Novus Now:
- Financial Filings: Click Here
- Quote: Click Here
- Website: Click Here
- Investor's Page: Click Here
About PRAM
PRAM Insurance Services, Inc. was founded in 1989 by David P. Wilson. Dave has been in the insurance industry for over 40 years, and he has focused exclusively on prescription drug benefits since the beginning of PRAM when he identified a unique need for pharmacy cost containment in the marketplace.
For additional information on PRAM, please visit https://pram.com.
About Novus
Novus Acquisition & Development Corp. (NDEV), through its subsidiary WCIG Insurance, provides health insurance and related insurance solutions within the wellness and medical marijuana industries in states where legal programs exist. Novus has developed its infrastructure within many lines of the insurance business such as health, property & casualty, life, accident, and fixed annuities.
Novus' medical cannabis benefits package will work as outside developers and will not cultivate, handle, transport grow, extract, dispense, put up for sale, put on the market, vend, deliver, supply, circulate, or trade cannabis or any substances that violate the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws. The statements made about specific products have not been evaluated by the United States Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure, or prevent disease. All information provided on these press releases or any information contained on or in any product label or packaging is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional. Once a push notification is completed the transaction is solely between the state-licensed dispensary and the registered patient.
The state laws are in conflict with the federal Controlled Substances Act. The current administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws, allowing the use and distribution of medical marijuana. However, there is no guarantee that the current administration, nor any future administration, will not change this policy and decide to enforce the federal laws strongly.
Any such change in the federal government's enforcement of current federal laws could cause significant financial changes to Novus Medical Group. While we do not intend to harvest, distribute or sell cannabis or cannabis-related products, we may be harmed by a change in enforcement by federal or state governments.
Forward-Looking Statements
This release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Membership and providers may change, become inactive, or nonpaying from time to time. Novus disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor Contact Information
855-228-7355
Email: info@getnovusnow.com
SOURCE: Novus Acquisition and Development Corporation
View source version on accesswire.com:
https://www.accesswire.com/655983/Novus-Signs-Partnership-With-PRAM-a-Leading-Pharmacy-Consulting-and-Underwriting-Firm
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial of MTX-474 in Diffuse Cutaneous Systemic Sclerosis30.9.2026 19:00:00 CEST | Press release
PRINCETON, NJ / ACCESS Newswire / September 30, 2026 / PharmaNest, Inc. an AI-enabled digital pathology company specializing in the quantitative and spatial characterization of fibrosis and Mediar Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapies to halt and reverse fibrosis, today announced a collaboration to integrate advanced digital pathology into Mediar's ongoing EncompaSSc Phase 2 clinical trial of MTX-474 in patients with diffuse cutaneous systemic sclerosis (dcSSc). MTX-474 is a first-in-class human IgG1 monoclonal antibody designed to neutralize EphrinB2 signaling, a pathway implicated in myofibroblast activation, extracellular matrix (ECM) deposition and tissue remodeling known to drive fibrosis in SSc. The randomized, double-blind, placebo-controlled EncompaSSc Phase 2 study is evaluating the safety and efficacy of MTX-474 in patients with dcSSc. Under the collaboration, PharmaNest will apply its FibroNest™ AI-enabled digital path
Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans30.9.2026 15:50:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / September 30, 2026 / Innodata Inc. (Nasdaq:INOD) today announced the opening of a new R&D laboratory that is designed to generate the data needed to train the next generation of human-like robots and independently validate the performance data that robots generate internally. Innodata developed the lab in collaboration with Vicon, a leader in motion capture who consulted on the lab design and continues to provide technical consulting. The New Jersey-based lab is equipped with high-precision, low-latency infrared optical tracking cameras that measure movement down to the sub-millimeter level-a degree of accuracy that methods such as wearable inertial measurement unit (IMU) sensors and single-camera (monocular) video analysis typically cannot match. The lab addresses an urgent need for high-quality training data for humanoids, industrial robots, and other forms of physical AI. While many other data providers infer 3D motion by analyzing 2D video, Innodata
Clean Air Metals Files Interim Financial Statements for the Six Months Ended July 31, 202630.9.2026 00:45:00 CEST | Press release
THUNDER BAY, ON / ACCESS Newswire / September 29, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTC PINK:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the six-month period ended July 31, 2026, available for viewing on www.sedarplus.ca. Financial HighlightsTotal assets as at July 31, 2026 of $35,465,204Total cash as at July 31, 2026 of $422,500Working capital deficiency as at July 31, 2026 of $3,188,114Shareholder's equity as at July 31, 2026 of $31,803,864 During the six-month period ended July 31, 2026, the Company incurred $164,309 in cost for exploration activities at the Thunder Bay North project. During the second fiscal quarter, the Company focused on finalizing the proposed amalgamation while continuing discussions on Advanced Exploration permitting and re-assessment of past geophysical work to highlight areas of focus for drilling and geophysics in
Continent 8 and FuturePath AI Launch Future8: Accountable AI for Regulated Industries29.9.2026 15:00:00 CEST | Press release
LISBON, PT / ACCESS Newswire / September 29, 2026 / Continent 8 Technologies and FuturePath AI today launched Future8, an AI-native operating company built for regulated operators, formed as a joint venture between the two companies. Announced at SBC Summit Lisbon, Future8 combines FuturePath's enterprise AI applications platform with Continent 8's licensed global operating footprint, enabling the iGaming industry to deploy auditable AI without compromising compliance, data sovereignty and operational control. Built for highly regulated environments, Future8 enables operators to move from AI experimentation to production deployment by embedding governance, approvals and auditability into every workflow from day one. Continent 8 brings licensed data centers and a private global network spanning more than 100 locations, built over 28 years serving the biggest iGaming and online brands, along with AI-enabled Global Capability Centers in India, the Philippines and Bulgaria. The company als
Europe SPAC Summit 2026 Invites European Private Companies to Explore the SPAC Path to U.S. Public Markets29.9.2026 15:00:00 CEST | Press release
NEW YORK, NY AND ZURICH, SWITZERLAND / ACCESS Newswire / September 29, 2026 / A growing number of European companies in frontier technologies, critical minerals, advanced manufacturing, defense tech, energy, and consumer sectors are evaluating a merger with a special purpose acquisition company (SPAC) as a faster route to a U.S. listing, a valuation that reflects global investor demand, and access to follow-on capital. The Europe SPAC Summit 2026 (ESPAC'26), co-hosted by AUM Advisors and MBP Global, is inviting the CEOs, CFOs, founders, and board members of late-stage European private companies to The Dolder Grand in Zurich on Thursday, December 10, 2026, to learn how the process works and to meet the investment bankers, institutional investors, and SPAC sponsors who make these transactions happen. Attendance is by invitation only and free of charge for qualified companies. Europe's recent de-SPACs show what is possible. Kyivstar, Ukraine's largest mobile operator, listed on Nasdaq thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
